Little Children's Philadelphia Foundation to make Roche's concern

Little Children's Philadelphia Foundation to make Roche's concern

Philadelphia Children's Hospital wants to invest in clinical companies and researchers launched in a highway-the organization has received more than $ 450 million in order to own its own property at the company.

Philadelphia, based on Spark Therapeutics, announced on Monday that Roche had purchased it in a $ 4.8 billion agreement. Roche will buy companies for $ 114.50 per share in cash, 122% up to closing costs on February 22. Companies think the agreement closes the second quarter, depending on the closing and closing details.

The company is a company of companies that specializes in treatments such as blindness, hemophilia, lysosomal respiratory and neurodegenerative diseases. The company started in March 2013, which was about 20 years ago to develop technology and research in CHOP, according to the website.

Since April 9, 2018, CHOP owned 10,7% of Spark shares, or approximately 4 million, as Fifa FIFA 2018 presented. At $ 114.50 per share, the Foundation stands to receive more than $ 450 million to invest. The hospital hospital fund was $ 6.7 billion at the end of 2018, mainly at the end of the year. The CHOP staff did not provide information on the agreement.

With the launch of a drug resistant, a recovery of patients with a terminal illness, Spark became the first expert in technology to ensure the successful transmission of the virus in the U.S. and U.S ..

Spark CEO Jeffrey Marrazzo said in a statement that his company had built unknowingly unleashed levels.

"But the needs of patients with families with pneumonia are fast and many," he said. "With its global strength and rich resources, Roche will help us continue to develop antibiotics for more patients for more infections and more rapidly seeing the world's perspective that no virus is immune to infections. "

Faculty of Technology, Federico Mingozzi, studied the liver's attitude with the virus infections in CHOP, and participated in the first clinical study in person based on the adeno science system.

Dr. Katherine High, director of research and development, has been the director of the CHOP's Center for Chemicals and Prevention, where she worked on pesticides for a variety of antibiotics.

In the email, Roche Simone Oeschger says that Roche is suffering from spark because of the risk of diabetes that can be transmitted to the patients, in one and a half cases.

"Our long-term commitment to providing a diversity of care for patients in essential ways has allowed us to become more active in areas related to diseases, infections and viruses," she said. "Physical Health Care Representatives represent Roche's representation for spreading and translating a file to the world."

Oeschger says Roche is working in the modern revolutionary environment since he was in the 4D group of biologists.

According to the Spark Company of 2018, the company paid 6.1 billion dollars in 2017 under the current agreement. Spark signed a license agreement with CHOP in October 2013 which was adjusted several times. In November 2015, Spark entered into a license agreement with CHOP who issued international authorization, with copyright, and the application of application application application that was based on the production of the virus.

Spark chairman, Dr. Steven Altschuler, former chairman of CHOP College and CHOP Foundation. It made $ 285,000 in cash and stock premiums as its position in 2017.

Spark price prices increased by 120% on Monday to $ 113.49 per day as mid-mid, compared to $ 51.56 in the market near Friday and # 39 on February 22.